ACT Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained, large TTM revenue growth indicates material demand expansion and improving market penetration across end markets. Over 2–6 months this durable top-line expansion supports scale economics, greater pricing leverage, and the ability to fund capacity or product development without relying on external finance.
Balance Sheet StrengthA zero-debt balance sheet materially reduces financial risk and gives management flexibility to invest, weather cycles, or pursue M&A. Over the medium term this conservatism supports stable operations, lower interest sensitivity, and the capacity to finance growth internally if cash conversion normalizes.
High Returns & ProfitabilityRobust margins and an attractive ROE reflect competitive specialization and efficient capital use. Persistently solid profitability creates durable internal funding for R&D and capex, allows reinvestment into specialty product lines, and supports resilience versus commodity peers over the coming months.
Bears Say
Weak Free Cash Flow ConversionDespite strong operating cash flow, near-zero TTM free cash flow implies elevated capex or working-capital absorption. Over the medium term this constrains the company’s ability to self-fund expansion, pay sustained dividends, or build cash buffers unless conversion improves.
Margin VolatilityMaterial margin swings point to exposure to input costs, pricing/mix shifts, or product cycle effects. This structural earnings variability makes forecasting and capital allocation harder and can erode returns if adverse cost dynamics persist over the next several quarters.
Expanding Asset Base Needs Sustained ReturnsA growing asset base dilutes returns unless incremental investments maintain high utilization and margins. If new capacity underperforms or margins slip, ROE and cash generation could weaken, making recent profitability and growth harder to sustain beyond a few quarters.
AlzChem Group AG News
ACT FAQ
What was AlzChem Group AG’s price range in the past 12 months?
Currently, no data Available
What is AlzChem Group AG’s market cap?
AlzChem Group AG’s market cap is CHF1.60B.
When is AlzChem Group AG’s upcoming earnings report date?
AlzChem Group AG’s upcoming earnings report date is Jul 30, 2026 which is in 16 days.
How were AlzChem Group AG’s earnings last quarter?
AlzChem Group AG released its earnings results on Apr 30, 2026. The company reported CHF1.641 earnings per share for the quarter, the consensus estimate of CHF1.641 by CHF0.
Is AlzChem Group AG overvalued?
According to Wall Street analysts AlzChem Group AG’s price is currently Undervalued.
Does AlzChem Group AG pay dividends?
AlzChem Group AG does not currently pay dividends.
What is AlzChem Group AG’s EPS estimate?
AlzChem Group AG’s EPS estimate is 1.54.
How many shares outstanding does AlzChem Group AG have?
Currently, no data Available
What happened to AlzChem Group AG’s price movement after its last earnings report?
AlzChem Group AG reported an EPS of CHF1.641 in its last earnings report, expectations of CHF1.641. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of AlzChem Group AG?
Currently, no hedge funds are holding shares in CH:ACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AlzChem Group AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF186.04 (― Downside)
CHF186.04 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.64%
12-Months-Change
Fundamentals
Return on Equity
27.13%
Trailing 12-Months
Asset Growth
17.58%
Trailing 12-Months
Company Description
AlzChem Group AG
AlzChem Group AG operates globally, engaging in the development, production, and distribution of a wide array of chemical products through its subsidiaries. The company's reach extends across Germany, the European Union, the rest of Europe, Asia, the NAFTA region, and other international markets. Its business is organized into three primary divisions: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The diverse product portfolio includes prominent dietary supplements such as Creapure® and Alipure®, along with the creatine-based LIVADUR®. For animal nutrition, AlzChem supplies Creamino®, a guanidinoacetic acid preparation. The pharmaceutical industry benefits from its Bioselect® brand. Industrial applications feature DYHARD® curing agents, acting as accelerators in adhesives, powder coatings, printed circuit boards, and composites, while SILZOT® silicon nitride is vital for ceramics, electronics, and solar technology. The company also manufactures a variety of fine and foundational chemicals, encompassing products derived from calcium carbide, calcium cyanamide (marketed as PERLKA®), hydrogen cyanamide, dicyandiamide, guanidine, guanamines, nitroguanidine, and various aromatic and aliphatic nitriles. Its agricultural offerings include ALZOGUR® germicide for pig pens, Dormex® and Sitofex® plant growth regulators, and BREAK-THRU® plant protection additives. Furthermore, AlzChem provides crucial products for hot metal desulfurization and secondary metallurgy, in addition to technical gases. Beyond its core chemical activities, the group also oversees chemical park operations, offers administrative assistance, and delivers a range of infrastructure services. Established in 1908, AlzChem Group AG maintains its headquarters in Trostberg, Germany.
ACT Stock 12 Month Forecast
Average Price Target
CHF186.04
Options Prices
Currently, No data available
---